IP Library › Granted Patent US 7,459,279
Granted Patent B2
US 7,459,279 · App. 11/170,153 · Granted Dec 2, 2008

Binding assay employing IGS4, a human G-protein coupled neuromedin receptor

Assignee: Solvay Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,279
App. No.
11/170,153
Granted
Dec 2, 2008
Kind
B2
Abstract

The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such- polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the G-protein coupled receptor family, referred to as G-family. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS 4 -gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS 4 . The invention also relates to the identification of the cognate ligand of the IGS 4 polypeptides of the invention. High affinity binding to said IGS 4 polypeptides is found for the neuropeptides known as neuromedin U.

Claims (7)

1. A method of determining whether a substance is a potential ligand of a neuromedin receptor comprising:

(a) contacting cells expressing the receptor chosen from SEQ ID NO:2, SEQ ID NO:4 SEQ ID NO:6 or SEQ ID NO:8, or the polypeptide encoded by a DNA insert contained in the deposit no. CBS 102221 or the deposit no. CBS 102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands with labeled neuromedin U in the presence and in the absence of the substance;

or contacting a receptor membrane preparation comprising one of said receptors chosen from SEQ ID NO:2, SEQ ID NO:4 SEQ ID NO:6 or SEQ ID NO:8 or a polypeptide encoded by the DNA insert contained in the deposit no. CBS 102221 or the deposit no. CBS 102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands with labeled neuromedin U in the presence and in the absence of the substance; and

(b) measuring the binding of neuromedin U to the receptor.

2. A method of determining whether a substance is a potential ligand of a neuromedin receptor comprising:

(a) contacting a cell expressing the receptor chosen from SEQ ID NO:2, SEQ ID NO:4 SEQ ID NO:6 or SEQ ID NO:8, or the polypeptide encoded by a DNA insert contained in the deposit no. CBS 102221 or the deposit no. CBS 102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands with neuromedin U in the presence and in the absence of the substance; and

(b) determining whether intracellular calcium levels are modulated in the cell, wherein modulation of intracellular calcium levels indicates that the substance is a ligand of the receptor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2013
From: ABBOTT HEALTHCARE PRODUCTS B.V.
To: ABBVIE B.V.
Reel/Frame 030842/0727 →
Priority Claims (3)
EP 99203140 · Sep 24, 1999 · regional
NL 1013140 · Sep 24, 1999 · national
EP 00202683 · Jul 28, 2000 · regional
Continuity (3)
Division 1008874400
Provisional Application 6022204700 · Jul 31, 2000
Related Publication 20050266529A1 · Dec 1, 2005